FSHR
Follicle-stimulating hormone receptor
As of the edition of 20 October 2026, FSHR (follicle-stimulating hormone receptor, UniProt P23945) has 7 drugs tested at it and 2 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P23945
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Hormones; Cancer; Inherited and neonatal; Nutrition and metabolism; Heart and blood vessels
- Registered trials of its drugs
- 222
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Follitropin alfa | Marketed | Phase 4 | Ended 2009 |
| Corifollitropin alfa | Marketed | Phase 4 | none listed |
| Menotropins | Marketed | Phase 4 | Ended 1987 |
| Follitropin delta | Marketed | Phase 4 | none listed |
| Follitropin beta | Marketed | Phase 4 | Ended 2009 |
| Follitropin | Marketed | Phase 4 | none listed |
| Urofollitropin | Marketed | Phase 4 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| IBSA Institut Biochimique | Route B |
| Boiron | Route B |
The other 0 companies at FSHR
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at FSHR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.